Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Jaguar Animal Health, Inc. stock logo
JAGX
Jaguar Animal Health
$2.78
-13.9%
$6.26
$2.77
$110.75
$3.29M0.6851,731 shs196,643 shs
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
$0.39
$0.19
$28.00
$906K2.19462,687 shs2.25 million shs
Onconetix, Inc. stock logo
ONCO
Onconetix
$4.00
-2.4%
$6.02
$3.82
$1,190.00
$3.12M3.5108,408 shs392,031 shs
PainReform Ltd. stock logo
PRFX
PainReform
$1.70
-1.2%
$2.04
$1.68
$16.63
$3.46M0.631.44 million shs33,959 shs
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Jaguar Animal Health, Inc. stock logo
JAGX
Jaguar Animal Health
-13.93%-27.03%-51.74%-55.34%-97.16%
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
0.00%0.00%0.00%0.00%0.00%
Onconetix, Inc. stock logo
ONCO
Onconetix
-2.44%-31.60%-42.05%-63.88%-99.23%
PainReform Ltd. stock logo
PRFX
PainReform
-1.16%-15.00%-10.99%-38.41%-13.44%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Jaguar Animal Health, Inc. stock logo
JAGX
Jaguar Animal Health
2.2858 of 5 stars
3.55.00.00.00.60.00.6
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
N/AN/AN/AN/AN/AN/AN/AN/A
Onconetix, Inc. stock logo
ONCO
Onconetix
0.6477 of 5 stars
0.04.00.00.01.80.00.6
PainReform Ltd. stock logo
PRFX
PainReform
2.0285 of 5 stars
3.04.00.00.00.61.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Jaguar Animal Health, Inc. stock logo
JAGX
Jaguar Animal Health
3.00
Buy$60.002,058.27% Upside
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
0.00
N/AN/AN/A
Onconetix, Inc. stock logo
ONCO
Onconetix
0.00
N/AN/AN/A
PainReform Ltd. stock logo
PRFX
PainReform
2.00
Hold$8.00370.59% Upside

Current Analyst Ratings Breakdown

Latest NEPT, ONCO, PRFX, and JAGX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/19/2025
Jaguar Animal Health, Inc. stock logo
JAGX
Jaguar Animal Health
First Berlin
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$60.00
(Data available from 6/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Jaguar Animal Health, Inc. stock logo
JAGX
Jaguar Animal Health
$11.69M0.24N/AN/A$12.29 per share0.23
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
$52.62M0.00N/AN/A($91.90) per share0.00
Onconetix, Inc. stock logo
ONCO
Onconetix
$2.52M1.21N/AN/A$11.22 per share0.36
PainReform Ltd. stock logo
PRFX
PainReform
N/AN/AN/AN/A$2.08 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Jaguar Animal Health, Inc. stock logo
JAGX
Jaguar Animal Health
-$38.49MN/A0.00N/AN/A-343.92%-432.91%-71.25%8/12/2025 (Estimated)
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
-$60.46M-$106.72N/AN/AN/A-128.13%N/A-141.94%N/A
Onconetix, Inc. stock logo
ONCO
Onconetix
-$58.69MN/A0.00N/A-2,913.71%-514.04%-75.82%8/27/2025 (Estimated)
PainReform Ltd. stock logo
PRFX
PainReform
-$14.59M-$147.33N/AN/AN/AN/AN/A8/13/2025 (Estimated)

Latest NEPT, ONCO, PRFX, and JAGX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
6/12/2025Q1 2025
Onconetix, Inc. stock logo
ONCO
Onconetix
N/A$21.25N/A-$0.53N/A$0.10 million
5/15/2025Q1 2025
Jaguar Animal Health, Inc. stock logo
JAGX
Jaguar Animal Health
-$18.50-$16.70+$1.80-$16.70$3.29 million$3.50 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Jaguar Animal Health, Inc. stock logo
JAGX
Jaguar Animal Health
N/AN/AN/AN/AN/A
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
N/AN/AN/AN/AN/A
Onconetix, Inc. stock logo
ONCO
Onconetix
N/AN/AN/AN/AN/A
PainReform Ltd. stock logo
PRFX
PainReform
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Jaguar Animal Health, Inc. stock logo
JAGX
Jaguar Animal Health
22.20
1.08
0.70
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
N/A
0.23
0.10
Onconetix, Inc. stock logo
ONCO
Onconetix
N/A
0.17
0.16
PainReform Ltd. stock logo
PRFX
PainReform
N/A
1.81
1.81

Institutional Ownership

CompanyInstitutional Ownership
Jaguar Animal Health, Inc. stock logo
JAGX
Jaguar Animal Health
12.04%
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
14.44%
Onconetix, Inc. stock logo
ONCO
Onconetix
23.89%
PainReform Ltd. stock logo
PRFX
PainReform
37.28%

Insider Ownership

CompanyInsider Ownership
Jaguar Animal Health, Inc. stock logo
JAGX
Jaguar Animal Health
0.38%
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
5.10%
Onconetix, Inc. stock logo
ONCO
Onconetix
3.10%
PainReform Ltd. stock logo
PRFX
PainReform
34.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Jaguar Animal Health, Inc. stock logo
JAGX
Jaguar Animal Health
501.02 million1.01 millionNo Data
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
584.53 million4.30 millionNot Optionable
Onconetix, Inc. stock logo
ONCO
Onconetix
12760,000738,000N/A
PainReform Ltd. stock logo
PRFX
PainReform
42.01 million1.32 millionNot Optionable

Recent News About These Companies

PainReform Ltd.
PainReform announces expansion into SEM sector
PainReform says shareholder equity now exceeds required threshold
PainReform Provides Year-End Business Update
PainReform completes acquisition of DeepSolar

New MarketBeat Followers Over Time

Media Sentiment Over Time

Jaguar Animal Health stock logo

Jaguar Animal Health NASDAQ:JAGX

$2.78 -0.45 (-13.93%)
Closing price 06/18/2025 04:00 PM Eastern
Extended Trading
$2.97 +0.19 (+6.80%)
As of 06/18/2025 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company's products include Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing NP-300, a second-generation antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.

Neptune Wellness Solutions stock logo

Neptune Wellness Solutions NASDAQ:NEPT

Neptune Wellness Solutions Inc., a health and wellness products company, specializes in the extraction, purification and formulation of cannabis products, as well as other specialty ingredients, such as MaxSimil, a patented ingredient that enhances the absorption of lipid-based nutraceuticals, and various other marine and seed oils. Its custom formulations are available in various delivery forms, such as softgels, liquid solutions, nutritional emulsions, and chewables. Neptune Wellness Solutions Inc. was founded in 1998 and is headquartered in Laval, Canada.

Onconetix stock logo

Onconetix NASDAQ:ONCO

$4.00 -0.10 (-2.44%)
Closing price 06/18/2025 04:00 PM Eastern
Extended Trading
$4.11 +0.11 (+2.75%)
As of 06/18/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.

PainReform stock logo

PainReform NASDAQ:PRFX

$1.70 -0.02 (-1.16%)
Closing price 06/18/2025 03:52 PM Eastern
Extended Trading
$1.72 +0.02 (+0.88%)
As of 06/18/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel.